Cognitive-Behavioral Treatments for Anxiety and Stress-Related Disorders.

Focus (Am Psychiatr Publ)

Department of Psychiatry, Massachusetts General Hospital, Boston (all authors); Department of Psychiatry, Harvard Medical School, Boston (Curtiss, Baker).

Published: June 2021

Cognitive-behavioral therapy (CBT) is a first-line, empirically supported intervention for anxiety disorders. CBT refers to a family of techniques that are designed to target maladaptive thoughts and behaviors that maintain anxiety over time. Several individual CBT protocols have been developed for individual presentations of anxiety. The article describes common and unique components of CBT interventions for the treatment of patients with anxiety and related disorders (i.e., panic disorder, social anxiety disorder, generalized anxiety disorder, obsessive-compulsive disorder, posttraumatic stress disorder, prolonged grief). Recent strategies for enhancing the efficacy of CBT protocols are highlighted as well.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8475916PMC
http://dx.doi.org/10.1176/appi.focus.20200045DOI Listing

Publication Analysis

Top Keywords

anxiety disorders
8
cbt protocols
8
anxiety disorder
8
anxiety
7
cbt
5
disorder
5
cognitive-behavioral treatments
4
treatments anxiety
4
anxiety stress-related
4
stress-related disorders
4

Similar Publications

Unlabelled: The association of the pathogenesis of neurodegenerative diseases, depression, anxiety, and cognitive disorders with neurotrophin-3 deficiency determines the prospect of creating drugs with a similar mechanism of action. Since the use of full-length NT-3 is limited by unsatisfactory pharmacokinetic properties, the creation of low-molecular mimetics of neurotrophin-3 that are active when administered systemically is relevant. The Federal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies has created a dimeric dipeptide mimetic of the 4th loop of NT-3, hexamethylenediamide bis-(N-γ-oxybutyryl-L-glutamyl-L-asparagine) with the laboratory code GTS-302, which activates TrkC and TrkB receptors.

View Article and Find Full Text PDF

Introduction: The developed domestic retrodipeptide analogue of cholecystokinin tetrapeptide (CCK) (N-(6-phenylhexanoyl)-glycyltryptophan amide, or compound GB-115) with antagonistic properties in relation to CCK1 receptors has anxiolytic activity previously shown in preclinical and clinical studies. The aim of the study was to evaluate the anxiolytic effect of GB-115 as a tablet form with subchronic oral administration in comparison with phenazepam in nonhuman primates.

Materials And Methods: The study was conducted on four male rhesus monkeys (Macaca mulatta) aged 5.

View Article and Find Full Text PDF

Objectives: Women with preconception anxiety and/or depression experience high rates of relapse or recurrence of the disorders in the perinatal period. This review aimed to identify perinatal interventions that were designed to prevent relapse or recurrence in women with a history of anxiety and/or depression.

Methods: The review was conducted based on the PRISMA guidelines.

View Article and Find Full Text PDF

Objective: Posttraumatic stress disorder (PTSD) and more complex posttraumatic symptomatology (i.e., dissociative PTSD [D-PTSD] and complex PTSD [CPTSD]) are differently described in the (5th ed.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!